GlassScriptPhysician profile
Antonio Urbina
NPI 1730558065
$5,007.20
in general payments reported to CMS, 2019-2025
22 companies · $547 in 2025
The $547 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $153 · 2021: $301 · 2022: $373 · 2023: $956 · 2024: $2,406 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295 · Travel and Lodging: $1,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.56 |
| Travel and Lodging | $1,613.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,267.96 | 2019-2025 | Eysuvis, Precision7, Total30 |
| Bausch & Lomb Americas INC. | $819.04 | 2022-2025 | Infuse, Biotrue, Xiidra |
| Sun Pharmaceutical Industries INC. | $399.91 | 2019-2025 | Cequa, Xelpros |
| Novartis Pharmaceuticals Corporation | $271.60 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $265.76 | 2019-2021 | |
| Coopervision INC. | $167.87 | 2023-2025 | Myday Contact Lens, Misight Contact Lens |
| Harrow Eye, LLC | $165.01 | 2024 | Vevye |
| Abbvie INC. | $104.73 | 2022-2023 | Durysta |
| Oyster Point Pharma, INC. | $93.67 | 2022-2025 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $79.86 | 2019-2022 | |
| Biotissue Holdings INC. | $70.93 | 2020-2023 | |
| Dompe US, INC. | $63.59 | 2019-2025 | Oxervate |
| Shire North American Group INC | $46.02 | 2019 | |
| Sight Sciences, INC. | $32.26 | 2024 | Tearcare System |
| Rxsight INC | $29.12 | 2021-2023 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $24.33 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $21.07 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $20.79 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $20.73 | 2024 | |
| Kala Pharmaceuticals, INC. | $18.24 | 2021 | |
| Lkc Technologies, INC. | $14.43 | 2024 | |
| Tearlab Corp | $10.28 | 2023 | Tearlab Osmolarity System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Urbina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.